David A. Siegel 4 D Molecular Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 743,400 shares of FDMT stock, worth $7.86 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
743,400
Previous 490,400
51.59%
Holding current value
$7.86 Million
Previous $1.58 Million
74.23%
% of portfolio
0.01%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding FDMT
# of Institutions
122Shares Held
41.2MCall Options Held
19KPut Options Held
38.3K-
Black Rock Inc. New York, NY4.9MShares$51.8 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA4.63MShares$48.9 Million0.67% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.56MShares$48.2 Million0.37% of portfolio
-
Goldman Sachs Group Inc New York, NY4.16MShares$44 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.74MShares$28.9 Million0.0% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $342M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...